GBM-001
Glioblastoma · IDH-wildtype · EGFR/PTEN/TERT Engine · VIZASL v1
MEBICAL · EOSE Fleet · Day 95 · Real data · Cited · γ₁-anchored
MEBICAL · NEURO-ONCOLOGY← RESEARCH
Glioblastoma
γ₁ floor anchor
PHASES
SORRIES
BM
NPs
Molecular Engine + Treatment
IDH-wildtype (WHO 2021) PROVEN
IDH-wt + TERT + chr7gain/10loss = GBM. Median OS 14-16mo.
Louis et al. Neuro-Oncology 2021
Stupp Protocol PROVEN
RT 60Gy + TMZ concurrent → TMZ adjuvant x6. Standard 20yr.
Stupp 2005 NEJM n=573
TTFields (Optune) PROVEN
200kHz 18h/day. OS 20.9 vs 16.0mo + TMZ. FDA 2015.
Stupp 2017 JAMA EF-14 n=695
IL13Rα2 CAR-T OPEN
One CR intratumoral. Antigen loss on relapse. Phase I only.
Brown 2016 NEJM
Bevacizumab anti-VEGF OPEN
No OS benefit. Approved recurrent only.
Chinot 2014 NEJM AVAglio
Open Sorries — Click to Expand
S-1 SORRY-1 · Pseudoprogression vs True Progression
S-2 SORRY-2 · MGMT Testing Heterogeneity
S-3 SORRY-3 · BBB Drug Delivery
S-4 SORRY-4 · CAR-T Exhaustion in Brain
S-5 SORRY-5 · Antigen Loss After CAR-T
Biomarkers + Signal
See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.
Novel Patterns
Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.
GBM-001 · FORTRESS MODE · BBB+GLIOSIS ARMOR · γ₁ = 14.134725141734693
γ₁ = 14.134725141734693